Posts filtered by tags: GlaxoSmithKline[x]


 

Moncef Slaoui, head of Operation Warp Speed, reportedly resigns as the top US vaccine advisor at the request of Biden's transition team

Moncef Slaoui, chief advisor of Operation Warp Speed. Reuters Operation Warp Speed's chief advisor Monclef Slaoui has stepped down at the request of President-elect Joe Biden's transition team, CNBC reported, citing an unnamed official from the team.  Operation Warp Speed is President Donald Trump's vaccine initiative, which has dedicated $6 million to coronavirus "countermeasures," including vaccine development. Slaoui will stay for 30 days from Biden's inauguration on January 20 to help ...
Tags: Health, Politics, Politico, US, Trends, Department Of Defense, Bloomberg, Joe Biden, GlaxoSmithKline, Biden, Donald Trump, Cnbc, Reuters, US Food and Drug Administration, Department of Health and Human Services, Moderna


Global shares rally after the House approves $2,000 stimulus checks; UK markets hit 11-month highs after Brexit deal

House Speaker Nancy Pelosi. Tasos Katopodis/Getty Images Global shares rose after the House of Representatives approved a bill increasing stimulus checks for households from $600 to $2,000. US stock futures point to S&P 500 and Dow Jones opening at or near record highs later. Last week's deal between the UK and the EU on Brexit lifted London blue-chip stocks to their highest since the start of the year.  Visit Business Insider's homepage for more stories. Global stock markets rose on Tuesd...
Tags: Hong Kong, Europe, UK, London, Congress, US, Trends, Diageo, Unilever, Eu, European Union, Britain, United States, House, House Of Representatives, Astrazeneca


Sanofi, GlaxoSmithKline delay COVID-19 vaccine rollout to late 2021

Sanofi and GlaxoSmithKline pushed back the timeline for rolling out their coronavirus vaccine after finding it didn’t work as well in...
Tags: GlaxoSmithKline, Sanofi


GSK and Sanofi delay the expected rollout of their COVID-19 vaccine until late 2021 because of an insufficient response in older people. The US has ordered 100 million doses.

A volunteer receives an injection from a medical worker during the country's first human clinical trial for a potential vaccine against the novel coronavirus, at Baragwanath Hospital in Soweto, South Africa, June 24, 2020. REUTERS/Siphiwe Sibeko GlaxoSmithKline and Sanofi have delayed the potential rollout of their COVID-19 vaccine to the final months of 2021, after it didn't show a strong enough response in older people. Interim results for human studies showed an "insufficient respon...
Tags: UK, White House, US, Trends, Eu, West, Canada, Healthcare, Fda, GlaxoSmithKline, Pfizer, Vaccine, Sanofi, GSK, BARDA, Soweto South Africa


Coronavirus vaccine czar urges Black Americans to put aside concerns about the vaccine, saying 'nobody's being used as a guinea pig'

Moncef Slaoui, the head of White House operation "Warp Speed" seen during a press conference in the White House Rose Garden. MANDEL NGAN/AFP via Getty Images Moncef Slaoui, the head of the White House operation "Warp Speed" said in an interview Sunday that "nobody's being used as a guinea pig" as the COVID-19 vaccine inches closer to becoming available to some people in the US. CNN's Jake Tapper asked Slaoui about how the US planned to convince minority communities the vaccine was safe, gi...
Tags: Politics, Science, White House, US, Trends, Cnn, Pew, GlaxoSmithKline, Pfizer, Donald Trump, Pew Research Center, Afp, Jake Tapper, Tapper, Moderna, Slaoui


Coronavirus vaccine czar said Moderna will seek an emergency use authorization for its vaccine by the end of November

Moderna will seek emergency use authorization from the Food and Drug Administration for its COVID-19 vaccine by the end of the month, the coronavirus vaccine czar said Sunday. Moderna; Samantha Lee/Business Insider Moderna, the biotech company that last week announced the results of its COVID-19 vaccine, will apply with the Food and Drug Administration for an emergency use authorization by the end of the month, Moncef Slaoui, the head of the White House Operation "Warp Speed" said Sunday. ...
Tags: Science, News, Abc, US, Trends, Healthcare, Food And Drug Administration, Fda, GlaxoSmithKline, Pfizer, Vaccine, Abc News, Moderna, Slaoui, Moncef Slaoui, Connor Perrett


Americans will hopefully begin receiving the COVID-19 vaccine as early as December 11, 'Warp Speed' advisor says

Some Americans could "hopefully" receive the vaccine for COVID-19 as soon as December 11 or 12, Moncef Slaoui said Dado Ruvic/Reuters Moncef Slaoui, the head of the White House "Operation Warp Speed" said on Sunday that some Americans will begin receiving the vaccine for COVID-19 as soon as December 11.  A panel of outside experts that advises the FDA is expected to meet on December 10 to discuss Pfizer's application for an emergency use authorization, but it's not clear how quickly FDA wo...
Tags: Science, News, White House, Trends, Cnn, United States, Healthcare, Food And Drug Administration, Fda, GlaxoSmithKline, Pfizer, Jake Tapper, Moderna, Slaoui, Moncef Slaoui, Connor Perrett


'The train is running' on Covid vaccines despite transition delay, Warp Speed adviser says

Decisions are being made outside of the “political environment,” said Moncef Slaoui, former head of GlaxoSmithKline’s vaccines department.
Tags: GlaxoSmithKline, Moncef Slaoui


Operation Warp Speed bought 100 million doses of Pfizer's and Moderna's vaccines before results came in. That $3.5 billion bet is paying off.

President Donald Trump delivers remarks on Operation Warp Speed. Shealah Craighead, White House The US launched Operation Warp Speed, an initiative to deliver coronavirus shots to Americans, in May. The program has funded the manufacturing of six promising vaccine candidates while clinical trials are ongoing. That includes shots from Pfizer and Moderna. Both companies recently announced positive results from their final stage of clinical trials. Warp Speed plans to distribute doses as soon...
Tags: Science, News, Cdc, White House, US, Trends, Department Of Defense, Bloomberg, European Union, Joe Biden, Ap, New York Times, Wisconsin, World Health Organization, Michigan, Fda


Moderna's coronavirus vaccine can cause severe fatigue and aches and pains. Two top vaccine experts told us why they think you'll still take it.

Moderna COVID vaccine trial volunteer receives injection that could be the vaccine. Data's been released that provides an indication of possible side effects. Hans Pennink/AP Photo Moderna said its vaccine has side effects like muscle aches and fatigue. Experts say that if the vaccine prevents COVID-19, then mild or moderate side effects won't impact vaccine uptake. The experts said they're waiting on the full data before recommending Moderna's shot.  Visit Business Insider's homepage ...
Tags: Trends, Joe Biden, Philadelphia, Fda, GlaxoSmithKline, Pfizer, US Food and Drug Administration, GSK, Fitzpatrick, Children s Hospital, Goodman, Emergency Department, Paul Offit, Lisa Fitzpatrick, Moderna, Offit


Here's why a top infectious-disease expert says it's too soon to celebrate Pfizer's coronavirus vaccine

Steve Parsons-WPA Pool/Getty Images Pfizer's coronavirus vaccine candidate succeeded in the last stage of clinical trials, the New York drugmaker said Monday. While Pfizer said the results showed its vaccine was more than 90% effective at preventing COVID-19, the company did not release data from the interim analysis. William Haseltine, a longtime biotech executive and infectious-disease expert, told Business Insider that while this was "very welcome news," he also wants to see the data. ...
Tags: Health, New York, Science, US, Trends, Harvard, Healthcare, GlaxoSmithKline, Pfizer, Steve Parsons, Human Genome Sciences, Moderna, William Haseltine, Haseltine, ACCESS Health International, Andrew Dunn


Why a top infectious-disease expert says it's too soon to celebrate Pfizer's coronavirus vaccine

Steve Parsons-WPA Pool/Getty Images Pfizer's coronavirus-vaccine candidate succeeded in the last stage of clinical trials, the New York drugmaker said Monday. While Pfizer said the results showed its vaccine was more than 90% effective at preventing COVID-19, the company did not release data from the interim analysis. William Haseltine, a longtime biotech executive and infectious-disease expert, told Business Insider that while this was "very welcome news," he also wanted to see the data....
Tags: Health, New York, Science, US, Trends, Harvard, Healthcare, GlaxoSmithKline, Pfizer, Steve Parsons, Human Genome Sciences, Moderna, William Haseltine, Haseltine, ACCESS Health International, Andrew Dunn


US stock futures soar after Pfizer says its COVID-19 vaccine helps prevent the virus and following Biden's historic win

Mario Tama/Getty Images US stock futures rallied by more than 5% before the opening bell on Monday, after drugmaker Pfizer said trials of its COVID-19 vaccine showed it to be effective in preventing the disease.Global stocks already hit record highs earlier in the day, following Joe Biden's historic win in last week's US presidential election.Healthcare stocks led the charge higher, with Pfizer rising by as much as 14% in premarket trading.Visit Business Insider's homepage for more stories...
Tags: White House, Global, US, Trends, Joe Biden, Healthcare, Deutsche Bank, Astrazeneca, US Treasury, GlaxoSmithKline, Pfizer, Federal Reserve, Biden, Dow Jones, Chris Beauchamp, Mario Tama Getty


US stock futures soar after Pfizer says its COVID-19 vaccine helps prevent illness and following Biden's historic win

Mario Tama/Getty Images US stock futures rallied by more than 5% before the opening bell Monday after the drugmaker Pfizer said trials showed its coronavirus vaccine to be effective in preventing COVID-19.Global stocks already hit record highs earlier in the day, following Joe Biden's victory in last week's US presidential election.Healthcare stocks led the charge higher, with Pfizer rising by as much as 14% in premarket trading.Visit Business Insider's homepage for more stories.US stock f...
Tags: Global, US, Trends, Joe Biden, Healthcare, Astrazeneca, US Treasury, GlaxoSmithKline, Pfizer, Federal Reserve, Biden, Chris Beauchamp, Mario Tama Getty, Stephen Innes, Shalini Nagarajan


6 vaccine experts told us how they'll decide whether to get a coronavirus shot

Getty Business Insider asked six infectious-disease experts when they'd feel confident getting a coronavirus vaccine.  Their answers varied in terms of which data would convince them.  Richard Condit, a retired University of Florida virologist, said he'd trust the scientists making the critical regulatory decision. Ultimately, if they recommended people his age get the shot, he'd likely get it, he said.  Other experts wanted more. University of Pennsylvania's Dr. Paul Offit emphasized the...
Tags: Science, US, Trends, Public Health, Harvard, Healthcare, Food And Drug Administration, National Institutes of Health, Philadelphia, Fda, University of Pennsylvania, University of Florida, GlaxoSmithKline, Pfizer, Vaccine, Bill


Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More

It’s October: a time of days growing shorter, leaves changing color, and phone calls in the wee hours that rouse scientists from slumber notifying them they’ve won the highest honor in their fields.This week, the 2020 Nobel Prize in physiology or medicine was awarded to Harvey Alter, Michael Alton, and Charles Rice, whose research led to the discovery of the hepatitis C virus. Their work paved the way for blood tests and new medicines that can cure the infection. In chemistry, the Nobel was awa...
Tags: Deals, Startups, Cancer, Trends, Investing, Merck, It, Software, Alzheimer's Disease, Fda, National, GlaxoSmithKline, Pfizer, Biotech, Dementia With Lewy Bodies, Cystic Fibrosis


Trump's coronavirus vaccine czar envisions '3 waves' of coronavirus vaccine data and approvals. Here's how he sees the next 6 months playing out.

Moncef Slaoui, chief advisor of Operation Warp Speed Reuters Moncef Slaoui, the chief scientist for the US government's coronavirus vaccine initiative, anticipates three waves of vaccine data and approvals coming over the next six months.  "We'll have three waves of efficacy readouts and potentially three waves of emergency use authorizations or approvals," Moncef Slaoui, the policy advisor of Operation Warp Speed, said in a phone interview with Business Insider on Tuesday. Slaoui predicte...
Tags: Health, Science, US, Trends, Healthcare, Astrazeneca, Fda, GlaxoSmithKline, Pfizer, Biotech, Business Insider, Trump, Johnson Johnson, Sanofi, Soweto South Africa, Pharmaceutical


GlaxoSmithKline tells staff to turn off Covid app at work

The company tells BBC News the app is not needed because its workplaces are Covid-secure.
Tags: UK, News, BBC News, GlaxoSmithKline


Trump's coronavirus vaccine czar is siding with the FDA on safety standards that would make a vaccine approval unlikely if not impossible before the election

Dr Moncef Slaoui speaks at a White House press conference on May 15, 2020, announcing a program to rapidly develop a coronavirus vaccine. AP Photo/Alex Brandon The man in charge of the Trump administration's efforts to aid the development of coronavirus vaccines told Business Insider he supports a decision to require two months of safety data before approving any COVID-19 vaccine. "I do think it is appropriate to set the threshold of safety follow-up," Moncef Slaoui, the scientific head of...
Tags: Health, New York, Science, White House, US, Trends, Healthcare, Fda, GlaxoSmithKline, Pfizer, Biotech, Donald Trump, Anthony Fauci, Trump, US Food and Drug Administration, EUA


Trump's coronavirus vaccine czar is siding with the FDA on safety standards that make a vaccine approval unlikely if not impossible before the election

Dr Moncef Slaoui speaks at a White House press conference on May 15, 2020, announcing a program to rapidly develop a coronavirus vaccine. AP Photo/Alex Brandon The man in charge of the Trump administration's efforts to aid the development of coronavirus vaccines told Business Insider he supports a decision to require two months of safety data before approving any COVID-19 vaccine. "I do think it is appropriate to set the threshold of safety follow-up," Moncef Slaoui, the scientific head of...
Tags: Health, New York, Science, White House, US, Trends, Healthcare, Fda, GlaxoSmithKline, Pfizer, Biotech, Donald Trump, Anthony Fauci, Business Insider, Trump, US Food and Drug Administration


Trump's coronavirus vaccine czar is backing the FDA on safety standards that make a vaccine approval unlikely if not impossible before the election

Dr Moncef Slaoui speaks at a White House press conference on May 15, 2020, announcing a program to rapidly develop a coronavirus vaccine. AP Photo/Alex Brandon The man in charge of the Trump administration's efforts to aid the development of coronavirus vaccines told Business Insider he supports a decision to require two months of safety data before approving any COVID-19 vaccine. "I do think it is appropriate to set the threshold of safety follow-up," Moncef Slaoui, the scientific head of...
Tags: Health, New York, Science, White House, US, Trends, Healthcare, Fda, GlaxoSmithKline, Pfizer, Biotech, Donald Trump, Anthony Fauci, Business Insider, Trump, US Food and Drug Administration


Credit Suisse apologizes over reports a black performer dressed as a janitor danced at a birthday party for the bank's chairman

Urs Rohner, Credit Suisse chairman. MICHAEL BUHOLZER / Stringer / Getty Images Credit Suisse has apologized after a black performer reportedly danced on stage dressed as a janitor at a birthday party for the bank's chairman, Urs Rohner. Tidjane Thiam, the bank's former chief executive, walked out of the room during the performance, the New York Times reported. Thiam, who resigned in February following a spying scandal, was the only black executive in charge of a major bank. Credit Suisse s...
Tags: UK, Scandal, Finance, US, Trends, Banking, Spying, Racism, New York Times, Credit Suisse, Ubs, Bank, GlaxoSmithKline, Tidjane Thiam, Times, Chief Executive


Trump is using the coronavirus as an excuse to go full kleptocrat, and the GOP is going right along with him

President Trump and Jared Kushner during the G7 summit in Biarritz, France Stefan Rousseau/PA Images via Getty Images Trump has handled the coronavirus pandemic the way any kleptocrat would – by putting family in charge and keeping things as under wraps as possible in order to hide his team's incompetence. It also appears that companies and individuals with ties to the Trump administration have found ways to enrich themselves during this disaster. Go figure. When Democrats on the House Fin...
Tags: White House, Russia, US, America, Kodak, Trends, Gop, House, Moscow, SEC, Michigan, Goldman Sachs, GlaxoSmithKline, IAC, Donald Trump, Vanity Fair


China's Clover says its coronavirus vaccine candidate showed promise in animal test

An experimental coronavirus vaccine developed by China's Clover Biopharmaceuticals appeared to be safe and able to trigger immune responses in animal tests, researchers have said. The result of the study on monkeys comes months after Clover began an early stage human trial in Australia in June, as global drug makers race to develop a safe and effective vaccine that can protect people from the COVID-19 pandemic that has killed nearly 1 million people. Clover's vaccine candidate, which is partly...
Tags: News, Australia, China, Britain, GlaxoSmithKline, Clover, Clover Biopharmaceuticals


5 vaccine experts told us what they'd need to know before they'd feel comfortable taking a coronavirus shot

Getty Business Insider asked five infectious-disease experts when they'd feel confident getting a coronavirus vaccine.  Their answers varied in terms of what data would convince them.  Richard Condit, a retired University of Florida virologist, said he'd trust the scientists making the critical regulatory decision. Ultimately, if they recommend people his age get the shot, he'd likely get it, he said.  Other experts wanted more. University of Pennsylvania's Dr. Paul Offit emphasized the n...
Tags: Science, US, Trends, Public Health, Harvard, Healthcare, Food And Drug Administration, Philadelphia, Fda, University of Pennsylvania, University of Florida, GlaxoSmithKline, Vaccine, Bill, Centers For Disease Control And Prevention, Trump


Seattle Genetics Lands $1.72B From Merck in Pair of Cancer Drug Deals

Seattle Genetics is in line to receive $1.72 billion from Merck via a pair of deals, one for a cancer drug that’s still in development and the other for partial rights to a therapy that won FDA approval earlier this year.The larger of the two deals is for the drug still in clinical development, ladiratuzumab vedotin. According to terns announced Monday, the two companies have agreed to jointly develop that drug, both by itself and in combination with Merck (NYSE: MRK) blockbuster cancer drug pe...
Tags: Deals, Trends, Merck, Astrazeneca, Fda, GlaxoSmithKline, Biotech, Seattle, Life Sciences, Clinical Trials, Gilead Sciences, Bothell WA, Pembrolizumab, Daiichi Sankyo, Seattle Genetics, Takeda Pharmaceutical


Dow soars 440 points as sharp tech turnaround leads market-wide rebound

Spencer Platt/Getty Images US stocks climbed on Wednesday, ending a three-day sell-off that saw the Nasdaq composite decline more than 10%.Technology stocks led the market higher, just as they led the it lower during the tumultuous three-day period.Wednesday's big gainers included Tesla, Apple, Microsoft, and Amazon, which all climbed roughly 4%.Watch major indexes update live here.US stocks staged a strong rally on Wednesday after a three-day sell-off driven by tech shares led to a more t...
Tags: Apple, Amazon, Finance, Wall Street, US, Trends, Gold, Markets, Tesla, Astrazeneca, Stocks, Berkshire Hathaway, Warren Buffett, Wti, GlaxoSmithKline, Stock Market


Dow rebounds 650 points after 3-day sell-off driven by tech giants

Andrew Kelly/Reuters US stocks rebounded on Wednesday after a three-day sell-off driven by tech giants led to a more than 10% decline in the Nasdaq composite index.Apple climbed more than 3% after sliding below a $2 trillion market cap on Tuesday.Oil recouped a fraction of the sharp losses experienced on Tuesday, with West Texas Intermediate crude contracts climbing as much as 2.5%, to $37.69 per barrel.Watch major indexes update live here.US stocks rebounded on Wednesday after a three-day...
Tags: Apple, Finance, US, Trends, Investing, Markets, Tesla, Oil Prices, Astrazeneca, Stocks, Oil Price, GlaxoSmithKline, Stock Market, Morgan Stanley, Nasdaq, Dow Jones


Dow rebounds 400 points after 3-day sell-off driven by tech giants

Andrew Kelly/Reuters US stocks rebounded on Wednesday after a three-day sell-off driven by tech giants led to a more than 10% decline in the Nasdaq composite index.Apple climbed more than 3% after sliding below a $2 trillion market cap on Tuesday.Oil recouped a fraction of the sharp losses experienced on Tuesday, with West Texas Intermediate crude contracts climbing as much as 2.5%, to $37.69 per barrel.Watch major indexes update live here.US stocks rebounded on Wednesday after a three-day...
Tags: Apple, Finance, US, Trends, Investing, Markets, Tesla, Oil Prices, Astrazeneca, Stocks, Oil Price, GlaxoSmithKline, Stock Market, Morgan Stanley, Nasdaq, Dow Jones


US stocks rebound after 3-day sell-off driven by tech giants

Andrew Kelly/Reuters US stocks rebounded on Wednesday after a three-day sell-off driven by tech giants led to a more than 10% decline in the Nasdaq composite index.Tech giant Apple climbed more than 3% after sliding below the $2 trillion market cap threshold on Tuesday.Oil recouped a fraction of the sharp losses experienced on Tuesday, with WTI crude contracts climbing as much as 2.5%, to $37.69 per barrel.Watch major indexes update live here.US stocks rebounded on Wednesday after a three-...
Tags: Apple, Finance, US, Trends, Investing, Markets, Tesla, Oil Prices, Astrazeneca, Stocks, Oil Price, GlaxoSmithKline, Stock Market, Morgan Stanley, Nasdaq, Dow Jones